Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Gilead Sciences
- Study ID
- NCT06051617
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Primary Biliary Cholangitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Seladelpar — DRUG* Seladelpar 10 mg one capsule daily for up to 36 months in participants with CP-A cirrhosis or * Seladelpar 5 mg one capsule daily for up to 36 months in participants with CP-B cirrhosis.
- Placebo — DRUGOne capsule daily for up to 36 months.
Study Details
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
Key Dates
- First listed
- Sep 25, 2023
- Start date
- Sep 7, 2023
- Status verified
- Aug 2026
- Primary completion
- Aug 31, 2030
- Completion
- Aug 31, 2030
Study Design
- Enrollment
- 318 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Seladelpar
- Placebo Comparator: Placebo
Primary Outcome Measure
Event Free Survival (EFS) [ Time Frame: 36 months ]
Central Contacts
- Gilead Clinical Study Information Center1-833-445-3230 (GILEAD-0)
Locations (52)
Find similar trials in Birmingham, AL
By research site
University of Alabama at Birmingham· Birmingham, ALSt. Joseph's Hospital and Medical Center - 350 W. Thomas· Phoenix, AZOM Research LLC· Lancaster, CACedar Sinai Medical Center· Los Angeles, CASCPMG/Kaiser Permanente Los Angeles Medical Center· Los Angeles, CACalifornia Liver Research Institute· Pasadena, CA
Related Studies
- A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing TreatmentRecruiting · Ipsen · Coronado, California
- Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical OutcomesPHASE3 · Recruiting · Zydus Therapeutics Inc. · Marietta, Georgia